지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.1
- 수록면
- 31 - 35 (5page)
이용수
초록· 키워드
오류제보하기
Background and Objectives: Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers.
Unfortunately, at their time of diagnosis, most patients have advanced to unresectable disease with a very poor prognosis.
The oriental herbal medicine HangAm-Plus (HAP) has been developed for antitumor purposes, and several previous studies have reported its therapeutic effects. In this study, the efficacy of HAP was evaluated as a third-line treatment for advanced-stage IIIb/IV NSCLC.
Methods: The study involved six patients treated at the East-West Cancer Center (EWCC) from April 2010 to October 2011.
Inoperable advanced-stage IIIb/IV NSCLC patients received 3,000 or 6,000 mg of HAP on a daily basis over a 12-week period.
Computed tomography (CT) scans were obtained from the patients at the time of the initial administration and after 12weeks of treatment. We observed and analyzed the patients overall survival (OS) and progression-free survival (PFS).
Results: Of the six patients, three expired during the study,and the three remaining patients were alive as of October 31,2011. The OS ranged from 234 to 512 days, with a median survival of 397 days and a one-year survival rate of 66.7%. In the 12-week-interval chest CT assessment, three patients showed stable disease (SD), and the other three showed progressive disease (PD). The PFS of patients ranged from 88 to 512 days,the median PFS being 96 days. Longer OS and PFS were correlated with SD. Although not directly comparable, the OS and the PFS of this study were greater than those of the docetaxel or the best supportive care group in other studies.
Conclusion: HAP may prolong the OS and the PFS of inoperable stage IIIb/IV NSCLC patients without significant adverse effects. In the future, more controlled clinical trials with larger samples from multi-centers should be conducted to evaluate the efficacy and the safety of HAP.
목차
등록된 정보가 없습니다.
참고문헌 (27)
참고문헌 신청
Cancer Care / / Types of lung cancer
Cancer Therapy Evaluation Program. / / Common Terminology Criteria for Adverse Events, Version 3.0
Cho JH. / 2004 / Clinical study in 320 cases for cancer patients on the effect Hangamdan / Collect Dissert Daejeon University 12 (2) : 157 ~ 175
Choi BL. / 2001 / The clinical study in 62 cases for lung cancer patients on the effects by Hangamdan / Collect Dissert Daejeon University 10 (1) : 121 ~ 131
Driscoll JJ. / 2009 / Overall survival : still the gold standard : why overall survival remains the definitive end point in cancer clinical trials / Cancer J 15 (5) : 401 ~
Cancer Therapy Evaluation Program. / / Common Terminology Criteria for Adverse Events, Version 3.0
Cho JH. / 2004 / Clinical study in 320 cases for cancer patients on the effect Hangamdan / Collect Dissert Daejeon University 12 (2) : 157 ~ 175
Choi BL. / 2001 / The clinical study in 62 cases for lung cancer patients on the effects by Hangamdan / Collect Dissert Daejeon University 10 (1) : 121 ~ 131
Driscoll JJ. / 2009 / Overall survival : still the gold standard : why overall survival remains the definitive end point in cancer clinical trials / Cancer J 15 (5) : 401 ~
이 논문의 저자 정보
최근 본 자료
댓글(0)
0